SLU-PP-332
ERR agonist
An experimental 'exercise mimetic' that activates estrogen-related receptors — animal data only.
Class
Estrogen-related receptor (ERR) agonist
Half-life
Not characterised in humans
Evidence
In-vitro / mechanistic
In-vitro / mechanistic
Cell-culture or mechanistic work only. No meaningful in-vivo human evidence exists.
Overview
SLU-PP-332 is a small molecule (not a peptide) that activates estrogen-related receptors (ERRα/β/γ), transcription factors central to mitochondrial biogenesis and oxidative metabolism. It is one of the newer 'exercise in a bottle' candidates: in mice it increased endurance, energy expenditure, and fat oxidation without exercise.
The gap between that and human use is total — there are no human studies. ERRs also play roles in the heart, and chronically activating a master metabolic transcription factor has unknown long-term consequences in people. It is sold as a research chemical with no human dosing or safety basis.
How it works
- Agonises ERRα/β/γ, driving mitochondrial biogenesis and oxidative gene programs.
- Increases fatty-acid oxidation and energy expenditure in muscle (in animal models).
- Mimics some transcriptional effects of endurance exercise.
What the research shows
Researched effects
- Increased running endurance and energy expenditure in mice
- Reduced fat mass without changing food intake in animal models
- No human efficacy or safety data
Limitations & what it won't do
- No human studies of any kind.
- ERR activation affects cardiac tissue; long-term human safety unknown.
- Not a peptide; not FDA approved.
Dosing protocols
These ranges reflect published trials and community protocols. They are reference information, not a prescription. Doses are per injection unless noted.
No established human protocol
Not establishedThere is no human pharmacokinetic or safety data to anchor any dose. The honest guidance is that this is preclinical.
Administration
Not an injectable reconstitution compound
Side effects
Common
- Unknown — no human data
Serious / rare
- Unknown — cardiac ERR activation is a theoretical concern
Contraindications & interactions
Do not use if you have
- Pregnant, breastfeeding, or trying to conceive
No safety data of any kind.
- Cardiovascular disease
ERR activation affects cardiac metabolism; avoid with cardiovascular disease pending human data.
Use caution if you have
- Arrhythmia or palpitations
Cardiac transcriptional effects are uncharacterised in humans.
What to monitor
- Realistic expectations — there is no human evidence
Commonly combined with
References
Research & educational information only — not medical advice.
You must be 18 or older to use this site. The peptides described are presented as research chemicals intended for research purposes only. Most are not approved by the FDA for human use. Dosing ranges reflect what has appeared in the scientific literature or community protocols and are not prescriptions. Nothing here replaces evaluation by a licensed physician who knows your full medical history.
Want to know if SLU-PP-332 fits your goals and history?
The assessment cross-checks your medical history and medications against this and every other compound before it recommends anything.
Start the assessment